Drupel Pharmaceutical Private Limited - Due diligence report

A 360° intelligence report on Drupel Pharmaceutical Private Limited: trust score, financial health, credit view, compliance, directors, grow…

2019-09-09 Gmc, Assam Active Unlisted
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Drupel Pharmaceutical Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
86/100
Trust Score
Low Risk

Drupel Pharmaceutical Private Limited is assessed as Low Risk with a Trust Score of 86/100. Drupel Pharmaceutical Private Limited is an active private limited indian non-government company incorporated in 2019, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 23 Oct 2026 from the latest processed filings. Drupel Pharmaceutical Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
86/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 3 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SUBIR GHOSH 01234567 Director 01/04/2018 6 yrs Approved
SANJOY GHOSH 01234567 Director 01/04/2018 6 yrs Approved
SUJAY GHOSH 01234567 Director 01/04/2018 6 yrs Approved
DEBAJIT KAR 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 90 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 2 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Operating for 7 years.
Active GST registration(s).
Distress signals & risk flags
No critical warning flags detected in the available data.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence88/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment68/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 7 events
29 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
01 Oct 2020
Director appointed
SANJOY GHOSH (Director)
Director appointed
SUJAY GHOSH (Director)
09 Sep 2019
Incorporated
Registered with Roc Guwahati
Director appointed
SUBIR GHOSH (Director)
Director appointed
DEBAJIT KAR (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 2 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Aashirwad Chlorofins Private Limited U24230HR2011PTC066151 Panipat, Haryana, India
Osho International Private Limited U51397DL1997PTC084824 Delhi, Delhi, India
Vivisano Life Sciences Private Limited U24233TG2021PTC155897 Hyderabad, Telangana, India
Sunbird Healthcare Private Limited U24233CT2016PTC002077 Raipur, Chattisgarh, India
Evestin Healthcare Private Limited U74999MH2016PTC288838 Nagpur, Maharashtra, India
Biorange Biologicals Private Limited U51909DL2020PTC374022 Delhi, Delhi, India
Visha Pharmaceuticals Private Limited U51397BR2007PTC012850 Patna, Bihar, India
Rudolf Life Sciences Private Limited U51909HR2014PTC052399 Panipat, Haryana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Drupel Pharmaceutical Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Drupel Pharmaceutical Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Drupel Pharmaceutical Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 86/100, distress signals and MSME payment-delay disclosures - know whether Drupel Pharmaceutical Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Drupel Pharmaceutical Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Drupel Pharmaceutical Private Limited an active company?

Drupel Pharmaceutical Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Drupel Pharmaceutical Private Limited financially healthy?

Drupel Pharmaceutical Private Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Drupel Pharmaceutical Private Limited?

Its overall Trust Score is 86/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Drupel Pharmaceutical Private Limited?

See the directors and ownership sections above for board and shareholding detail. 4 active director(s) are on record.

Does Drupel Pharmaceutical Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Drupel Pharmaceutical Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2025). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Drupel Pharmaceutical Private Limited?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.